{"DataElement":{"publicId":"7034808","version":"1","preferredName":"Surgical Patient Clinical Trial Eligibility Criteria Low Grade Glioma To Malignant Glioma Likely Disease Progression Indicator","preferredDefinition":"Indicator of whether surgical patient's low-grade glioma is likely to progress to malignant glioma.","longName":"ELIG_LOHI_PROG_IND","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"7034805","version":"1","preferredName":"Surgical Patient Clinical Trial Eligibility Criteria Low Grade Glioma To Malignant Glioma Likely Disease Progression","preferredDefinition":"of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma._Used as a function word to indicate direction, purpose, or movement._A malignant neuroglial neoplasm. The term can apply to several primary neoplasm of the brain and spinal cord, including astrocytoma and oligodendroglioma in addition to others._Having a good chance of being the case or of coming about._The worsening of a disease over time.","longName":"7034806v1.0:7034807v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"7034806","version":"1","preferredName":"Surgical Patient Clinical Trial Eligibility Criteria","preferredDefinition":"of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.:A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C25698:C16960:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical","conceptCode":"C25698","definition":"of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96215D39-17E5-311D-E053-F662850A34EE","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-30","modifiedBy":"ONEDATA","dateModified":"2019-10-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7034807","version":"1","preferredName":"Low Grade Glioma To Malignant Glioma Likely Disease Progression","preferredDefinition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.:Used as a function word to indicate direction, purpose, or movement.:A malignant neuroglial neoplasm. The term can apply to several primary neoplasm of the brain and spinal cord, including astrocytoma and oligodendroglioma in addition to others.:Having a good chance of being the case or of coming about.:The worsening of a disease over time.","longName":"7034807v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade Glioma","conceptCode":"C132067","definition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Malignant Glioma","conceptCode":"C4822","definition":"A grade 3 or grade 4 glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Likely","conceptCode":"C85550","definition":"Having a good chance of being the case or of coming about.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9628FF28-5104-7A4E-E053-F662850A3444","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-30","modifiedBy":"ONEDATA","dateModified":"2019-10-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9625239C-419B-7FD7-E053-F662850A94E7","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-30","modifiedBy":"TSESU","dateModified":"2022-07-06","changeDescription":"10/30/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"For surgical patient, if pati","type":"Preferred Question Text","description":"For surgical patient, if patient has a BRAF-V600 E or K mutated low grade glioma, is there a strong suspicion for progression to high grade?","url":null,"context":"ABTC"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"962604CC-1949-0452-E053-F662850ADC0E","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-30","modifiedBy":"TSESU","dateModified":"2022-07-07","changeDescription":"10/30/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}